Who are Baycol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Livalo, Lipitor, Mevacor, Zocor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cerivastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Baycol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Baycol (CERIVASTATIN) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cerivastatin. Area: Metabolic.

marketed cerivastatin 3-hydroxy-3-methylglutaryl-coenzyme A reductase Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Baycol (CERIVASTATIN) — Bayer.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Baycol TARGET	CERIVASTATIN	Bayer	marketed	cerivastatin	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1997-01-01
Livalo	PITAVASTATIN	Kowa Co	marketed	HMG-CoA Reductase Inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A reductase	2009-01-01
Lipitor	Atorvastatin Calcium	Pfizer	marketed	atorvastatin	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1996-01-01
Mevacor	LOVASTATIN	Merck & Co.	marketed	HMG-CoA Reductase Inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1987-01-01
Zocor	simvastatin	Merck & Co.	marketed	HMG-CoA Reductase Inhibitor [EPC]	Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-04-26 — Zocor · 10300041 · Formulation · US
2030-02-23 — Zocor · 9597289 · Formulation · US
2037-06-07 — Lipitor · 11654106 · US
2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (cerivastatin class)

Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Baycol — Competitive Intelligence Brief. https://druglandscape.com/ci/cerivastatin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing